SFS
BTAI icon

Sowell Financial Services’s BioXcel Therapeutics BTAI Stock Holding History

Sowell Financial Services’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-14
Closed -$7K – 827
2021
Q1 		$7K Buy
+14
New +$11.3K ﹤0.01% 2441

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $8.04B AUM 44.04% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Sowell Financial Services's BTAI Position: Q2 2021 in Review

Sowell Financial Services sold out of BioXcel Therapeutics (BTAI) in Q2 2021, closing a stake of 14 shares — an estimated $7K sold.

Sowell Financial Services first reported a position in BTAI in Q1 2021 and held it in 1 quarter. The position peaked at $7K in Q1 2021. 108 funds tracked by Wall St. Rank hold BTAI as of Q2 2021.

  • Sowell Financial Services reported no remaining BioXcel Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 14 BioXcel Therapeutics shares in Q2 2021, an estimated $7K.
  • Sowell Financial Services first reported a position in BioXcel Therapeutics in Q1 2021 and held it in 1 quarter.
  • Sowell Financial Services's BioXcel Therapeutics position peaked at $7K in Q1 2021.
  • 108 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.